Favipiravir In Adults with Moderate to Severe COVID-19: A Phase 3 Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial
Shenoy et al., medRxiv, doi:10.1101/2021.11.08.21265884
https://c19early.org/shenoy.html